Unique ID issued by UMIN | UMIN000026966 |
---|---|
Receipt number | R000030926 |
Scientific Title | Special drug use survey of Stelara for Crohn's disease |
Date of disclosure of the study information | 2017/05/31 |
Last modified on | 2023/07/13 09:38:31 |
Special drug use survey of Stelara for Crohn's disease
STL2L
Special drug use survey of Stelara for Crohn's disease
STL2L
Japan |
Crohn's disease
Gastroenterology |
Others
NO
The special drug use survey is aimed at investigating the safety and efficacy of the long-term use (52 weeks) of Stelara (including Intravenous Infusion 130 mg Vial and Subcutaneous Injection 45 mg Syringe, hereafter this product) for Crohn's disease in routine clinical practice. And follow up the patient for 3 years after administration of Stelara to investigate the incidence of malignancy.
Safety
Variables related to safety
a.Data on adverse reactions/infection
b.Data on serious adverse events
c.Data on adverse reactions of primary survey items
d.Factors possibly affecting the safety
e.Investigation of the safety in specific patient populations (the elderly, pregnant/nursing women, patients with renal impairment, patients with hepatic function disorder)
f.Data on adverse reactions of malignancy after long term of administration
Variables related to efficacy
a.Change in CDAI
b.Change in CRP
c.Result of endoscopy
d.Physician's Global Assessment
e.Effectiveness of changing administration interval
f.Factors possibly affecting the effectiveness
g.Investigation of the effectiveness in specific patient populations (the elderly, pregnant/nursing women, patients with renal impairment, patients with hepatic function disorder)
Observational
Not applicable |
Not applicable |
Male and Female
Patients who initiate Stelara Intravenous Infusion 130 mg Vial for moderate to severe active Crohn's disease (Only patients who have failed or were intolerant to previous treatment)
Patients with a history of the use of ustekinumab (active ingredient of this product)
300
1st name | Toshiya |
Middle name | |
Last name | Kato |
Janssen Pharmaceutical K.K.
Safety risk management dept
101-0065
5-2, Nishi-Kanda 3-chome, Chiyoda-ku, Tokyo
03-4411-5017
tkato1@its.jnj.com
1st name | Masayuki |
Middle name | |
Last name | Talagishi |
Janssen Pharmaceutical K.K.
Safety risk management dept
101-0065
5-2, Nishi-Kanda 3-chome, Chiyoda-ku, Tokyo
03-4411-5464
mtakagis@its.jnj.com
Janssen Pharmaceutical K.K.
Janssen Pharmaceutical K.K.
Profit organization
Janssen Pharmaceutical K.K.
5-2, Nishi-Kanda 3-chome, Chiyoda-ku, Tokyo
03-4411-5464
mtakagis@its.jnj.com
NO
2017 | Year | 05 | Month | 31 | Day |
Unpublished
Completed
2017 | Year | 05 | Month | 06 | Day |
2017 | Year | 05 | Month | 20 | Day |
2017 | Year | 05 | Month | 24 | Day |
2022 | Year | 04 | Month | 30 | Day |
Special drug use survey
2017 | Year | 04 | Month | 12 | Day |
2023 | Year | 07 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030926
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |